Ryvu Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Ryvu Therapeutics şirketinin toplam hissedar öz sermayesi PLN177.8M ve toplam borcu PLN80.5M olup, bu da borç-öz sermaye oranını 45.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla PLN403.2M ve PLN225.4M dir.

Anahtar bilgiler

45.3%

Borç/özkaynak oranı

zł80.52m

Borç

Faiz karşılama oranı	n/a
Nakit	zł247.55m
Eşitlik	zł177.75m
Toplam yükümlülükler	zł225.43m
Toplam varlıklar	zł403.18m

Son finansal sağlık güncellemeleri

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02

Recent updates

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Jan 25

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Feb 05

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Dec 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RVU 'nin kısa vadeli varlıkları ( PLN295.8M ) kısa vadeli yükümlülüklerini ( PLN97.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: RVU şirketinin kısa vadeli varlıkları ( PLN295.8M ) uzun vadeli yükümlülüklerini ( PLN127.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RVU şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: RVU şirketinin borç/öz sermaye oranı son 5 yılda 2% seviyesinden 45.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RVU şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: RVU serbest nakit akışı her yıl % 8.3 1.5 yıl yetecek nakit akışına sahip olacaktır.

Ryvu Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Recent updates

New minor risk - Share price stability

Third quarter 2024 earnings released: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023)

Ryvu Therapeutics Announces Dosing of the First Patient in the Remark Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

New major risk - Financial position

Second quarter 2024 earnings released: zł1.40 loss per share (vs zł1.23 loss in 2Q 2023)

Price target increased by 8.5% to zł77.95

Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024

First quarter 2024 earnings released: zł0.80 loss per share (vs zł0.79 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml

Ryvu Therapeutics S.A. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Share price stability

Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023

Third quarter 2023 earnings released

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings released

New major risk - Financial position

Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released

Price target increased by 13% to zł72.23

Price target increased by 8.7% to zł63.80

Ryvu Therapeutics S.A. to Report Q3, 2023 Results on Nov 29, 2023

Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.9 million in funding

Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Ryvu Therapeutics Announces Executive Changes

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 At the 2022 European Hematology Association Congress

Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Now 20% undervalued after recent price drop

Ryvu Therapeutics S.A. Presents Clinical and Translational Data Updates At the 63rd American Society of Hematology Annual Meeting and the 44Th San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Ryvu Therapeutics S.A. Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors

Ryvu Therapeutics S.A. Announces FDA Lifts Partial Clinical Hold on Phase IB Clinical Trial of RVU120 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Ryvu Therapeutics Presents Positive Phase I Data for Rvu120 of Phase I/Ii Data for Sel24 Presented by Development Partner Menarini

Ryvu Therapeutics Announces Results SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Ryvu Therapeutics S.A. Got Full Approval to Conduct Phase I/Ii Study of Rvu120 (Sel120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors in Poland

First quarter 2021 earnings released

Ryvu Therapeutics S.A. to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association

Full year 2020 earnings released

Ryvu Signs a Deal for Phase I Clinical Trials for its RVU120 Drug

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Ryvu Therapeutics S.A. to Report First Half, 2021 Results on Sep 08, 2021

Ryvu Therapeutics S.A. to Report Q3, 2021 Results on Nov 10, 2021

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

New 90-day low: zł49.00

New 90-day low: zł52.00

First half earnings released

New 90-day low: zł58.80

Ryvu Therapeutics S.A. Announces That the First Patient Has Been Treated in Europe for the Cohort Expansion Part of Phase Ii Diamond-01 Clinical Trial (Cli24-001; Nct03008187)

New 90-day low - zł60.00

Ryvu Therapeutics S.A. has completed a Follow-on Equity Offering in the amount of PLN 143.0547 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin